Evidence map›Paper›PMID 32555329›Full record

ArticleOncogene2020

AR and ERG drive the expression of prostate cancer specific long noncoding RNAs.

Annika Kohvakka, Mina Sattari, Anastasia Shcherban, Matti Annala, Alfonso Urbanucci, Juha Kesseli, Teuvo L J Tammela, Kati Kivinummi, Leena Latonen, Matti Nykter and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Androgen receptor and estrogen receptor variants in prostate and breast cancers.The Journal of steroid biochemistry and molecular biology · 2024
    Review
  4. Article
  5. Review
  6. The Expression of Proto-OncogeneInternational journal of molecular sciences · 2022
    Review
  7. Review
  8. Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Annika KohvakkaFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.
Mina SattariFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.ORCID http://orcid.org/0000-0001-7358-616X
Anastasia ShcherbanFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.
Matti AnnalaFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.
Alfonso UrbanucciDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0003-2931-3652
Juha KesseliFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.
Teuvo L J TammelaFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.
Kati KivinummiFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.ORCID http://orcid.org/0000-0002-5788-835X
Leena LatonenInstitute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Matti NykterFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.
Tapio VisakorpiFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland. tapio.visakorpi@tuni.fi.ORCID http://orcid.org/0000-0002-5004-0364
Tampere University Hospital · FIOslo University Hospital · NOUniversity of Eastern Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) play pivotal roles in cancer development and progression, and some function in a highly cancer-specific manner. However, whether the cause of their expression is an outcome of a specific regulatory mechanism or nonspecific transcription induced by genome reorganization in cancer remains largely unknown. Here, we investigated a group of lncRNAs that we previously identified to be aberrantly expressed in prostate cancer (PC), called TPCATs. Our high-throughput real-time PCR experiments were integrated with publicly available RNA-seq and ChIP-seq data and revealed that the expression of a subset of TPCATs is driven by PC-specific transcription factors (TFs), especially androgen receptor (AR) and ETS-related gene (ERG). Our in vitro validations confirmed that AR and ERG regulated a subset of TPCATs, most notably for EPCART. Knockout of EPCART was found to reduce migration and proliferation of the PC cells in vitro. The high expression of EPCART and two other TPCATs (TPCAT-3-174133 and TPCAT-18-31849) were also associated with the biochemical recurrence of PC in prostatectomy patients and were independent prognostic markers. Our findings suggest that the expression of numerous PC-associated lncRNAs is driven by PC-specific mechanisms and not by random cellular events that occur during cancer development. Furthermore, we report three prospective prognostic markers for the early detection of advanced PC and show EPCART to be a functionally relevant lncRNA in PC.

Indexed as

Gene Expression Regulation, NeoplasticCell Line, TumorCell MovementCell ProliferationDisease ProgressionHepatocyte Nuclear Factor 3-alphaHomeodomain ProteinsHumansMaleProspective StudiesProstatic NeoplasmsReceptors, AndrogenRNA InterferenceRNA, Long NoncodingTranscriptional Regulator ERGAR protein, humanERG protein, humanFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaHomeodomain ProteinsHOXB13 protein, humanReceptors, AndrogenRNA, Long NoncodingTranscriptional Regulator ERG

Identifiers

PMID32555329
OpenAlexW3036345150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.